Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), and several clinical trials have demonstrated the efficacy of CAR-Ts in this field. Experts are also debating the possibility of bringing CAR-T therapy into earlier lines of treatment, and ongoing clinical trials are evaluating the benefits of this.

In this exclusive podcast, leading experts David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, Caron Jacobson, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, and Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the current state of CAR-T therapy in lymphoma. The experts comment on moving CAR-T therapy into earlier lines of treatment, and discuss clinical trial updates, including results from the TRANSFORM study (NCT03575351) and the ZUMA-12 study (NCT03761056). This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.